Edition:
United States

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

5.61USD
18 Oct 2018
Change (% chg)

$-0.09 (-1.58%)
Prev Close
$5.70
Open
$5.71
Day's High
$5.71
Day's Low
$5.59
Volume
20,016
Avg. Vol
349,127
52-wk High
$17.30
52-wk Low
$4.95

Chart for

About

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)

Overall

Beta: 1.64
Market Cap(Mil.): $436.45
Shares Outstanding(Mil.): 82.82
Dividend: --
Yield (%): --

Financials

  TGTX.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -2.13 -- --
ROI: -160.75 1.96 12.83
ROE: -165.11 1.12 14.95

BRIEF-TG Therapeutics, Novimmune Announce Global Agreement For Development And Commercialization Of Anti-CD47/ Anti-CD19 bispecific antibody

* TG THERAPEUTICS AND NOVIMMUNE SA ANNOUNCE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF A NOVEL ANTI-CD47/ ANTI-CD19 BISPECIFIC ANTIBODY

Jun 20 2018

BRIEF-TG Therapeutics Reports Qtrly Loss Per Share Of $0.59

* TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

Competitors

Earnings vs. Estimates